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Abstract Nebulization simplifies the administration of effective inhaled medications to young asthmatics who 
experience hand-to-lung co-ordination problems and inspiratory difficulties associated with metered-dose and dry- 
powder inhalers, respectively.The objective of this double-blind, double-dummy, multicentre, randomized, parallel-group 
study was to compare the efficacy and safety of cot-ticosteroids given by nebulization or metered-dose inhalation in 
paediatric patients with exacerbation of asthma. Following a 24-h run-in period, I5 I patients, aged 6- I6 years, with 
moderate to severe exacerbation of asthma were randomized to one of two treatment groups for 4weeks: 
beclometasone dipropionate (BDP) suspension for nebulization I600 pgda)r’ b.i.d. given via a nebulizer (n=75), or BDP 
spray 800pgday-1 b.i.d. given via a metered-dose inhaler (MDI) plus spacer (BDP MDI) (n=76). Superimposable and 
statistically significant improvements over baseline were noted at study end for the two treatment groups in the various 
efficacy parameters evaluated (pulmonary function tests, asthma symptoms scores, and the use of rescue salbutamol).The 
primary efficacy endpoint was the morning pulmonary expiratory flow rate (PEFR). In the BDP nebulization group, mean 
morning PEFR increased statistically significantly from 233.2 f 86.3 I min-I to 322.0 & IO I .8 I rninp’, while in the BDP MDI 
group the increase was from 222.9 * 87.3 I min-’ to 3 14.9 + 96.6 I minm 1. Moreover, an additional 4-week treatment 
period at half doses, completed by 26 patients, demonstrated that improvements were maintained or further enhanced. 
The two treatments were equally well tolerated. A total of 25 and 26 patients in the BDP nebulization and BDP MDI 
groups, respectively, reported adverse events during the treatment period, and these were generally mild. In conclusion, 
the results of this tiudy demonstrate that BDP suspension for nebulization I600 pg day-1 given via a nebulizer and BDP 
spray 800 pg day-’ given via an MDI plus spacer are equally effective, with an acceptable safety and tolerability profile, when 
used in paediatric patients with moderate to severe asthma exacerbation. 
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INTRODUCTION 
Inhaled corticosteroids are recommended for the long- 
term control of asthma in children (I). However, many 
children are unable to use the available pressurized 
metered-dose inhalers (MDls) or dry-powder inhalers 
correctly or effectively, possibly resulting in under- 
treatment with anti-inflammatory drugs and overuse of 
oral steroids and inhaled P-agonists (I). Inhaled 
corticosteroids can be easily administered to paediatric 
asthmatics by nebulization, which can overcome the 
problems associated with other delivery systems (2,3). 
Indeed, nebulization of inhaled steroids now appears to 
be the most effective method for domiciliary treatment 
in young children with asthma. 
The purpose of this study was to compare the efficacy 
and safety of a new formulation of beclometasone 
dipropionate (BDP) suspension for nebulization 
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administered via a nebulizer with BDP spray 
administered via an MDI plus spacer (BDP MDI) in 
school-age children with moderate to severe exacer- 
bation of asthma. 
MATERIALS AND METHODS 
Male and female children, aged 2 6 to 5 I6 years, with a 
clinical diagnosis of exacerbation of asthma of moderate 
to severe degree [as defined by the National Heart, Lung 
and Blood Institute (4)], predicted normal forced 
expiratory volume in I second (FEV,) at study entry of 
between t 50% and I 80% (5), and a positive response to 
the reversibility test (defined as an increase of at least 
10% in FEV, measured I5 minutes following two puffs 
(2 x IOOpg) of inhaled salbutamol MDI) were eligible to 
participate in the study. Patients with evidence of 
symptomatic infection of the airways in the previous 
4 weeks, with the likelihood of exposure during the study 
to allergens or occupational sensitizing agents of a 
seasonal or episodic nature proven or suspected to affect 
the patients, with a history of clinically significant cardiac, 
renal, neurological, hepatic, or endocrine disease, treated 
with steroids in the previous 4 weeks (8 weeks for depot 
steroids), hypersensitive to inhaled corticosteroids, 
involved in another trial in the previous 4 weeks, and with 
2 + 15% increase in FEV, from start to end of the study 
run-in period were excluded from the randomization. 
Study design 
This was a 4-8-week, double-blind, double-dummy, 
randomized, controlled, open-labelled study undertaken 
in two parallel groups at six centres. Following a 24-h 
run-in period in which non-permitted medications were 
withdrawn, patients who met study entry criteria were 
assigned by randomization to one of the two treatment 
groups for a treatment period of 4 weeks: BDP 
suspension for nebulization I600 pg day-r b.i.d. (Clenil- 
A@, Chiesi Farmaceutici SpA, Italy), plus four puffs twice- 
daily of placebo spray, or BDP spray 800 pg day-r b.i.d. 
(four puffs twice-daily) (Becotide@, Allen & Hanburys, 
UK), plus placebo suspension for nebulization twice-daily. 
The suspension for nebulization was administered using 
a Pari Boy@ compressor and an LC Plus@ nebulizer (Pari 
Turbo Boy@) (Pari, Germany), and the spray was given via 
an MDI plus spacer (Volumatic@,Allen & Hanburys, U.K.). 
If required by the investigator, patients were allowed to 
continue treatment for an additional nonmandatory 
4 weeks at half doses. Theophylline, anticholinergics, 
inhaled (other than the test BDP) or oral cortico- 
steroids, long-acting inhaled bronchodilators, oral 
bronchodilators, oral antihistamines, and leukotriene 
antagonists were excluded.The use of inhaled salbutamol 
(Ventolin@, Glaxo-Wellcome, U.K.) given via an MDI, 
inhaled or oral sodium cromoglycate or nedocromil 
sodium in patients already receiving this, and appropriate 
treatment for concomitant disease if it did not interfere 
with study evaluation parameters was permitted. 
Patients were assessed at various clinic visits during the 
study: at the start of the run-in period, at the start of 
active treatment, and at I, 2, and 4 weeks post- 
randomization. An additional visit was made after 8 
weeks if the patients continued non-mandatory test 
treatment for a further 4 weeks. 
Lung function measurements were conducted 
according to the Official Statement of the European 
Respiratory Society (6) in the morning at approximately 
the same hour of the day. Spirometric lung function 
parameters were measured at each clinic visit. Morning 
and evening peak expiratory flow rates (PEFRs) were 
measured daily, before the administration of the test 
treatment, by patients using the Mini-Wright@ peak flow 
meter (Markos, Italy/Clement Clarke International, U.K.) 
and the highest of three measurements recorded on a 
diary card. Asthma symptoms scores, rated on a five- 
point scale (from 030 symptoms to 5=symptoms so 
severe that patient did not sleep/could not perform 
normal daily activities), and salbutamol consumption, 
were also assessed, twice-daily, by patients and recorded 
on a diary card. Patient and investigator opinions of 
efficacy, and investigator opinion of tolerability, were 
rated on a four-point scale ranging from ‘poor’ to 
‘excellent’ and recorded at study end. Morning serum 
cortisol levels were measured at the start and end of 
randomization, and vital signs at each clinic visit. The 
institutional review board for each treatment centre 
approved the protocol, and written informed consent 
was obtained from the parents or guardians of the 
patients. 
Assessments 
The primary efficacy endpoint was morning PEFR. 
Secondary efficacy variables were evening PEFR, FEV,, 
forced vital capacity (FVC), day- and night-time 
consumption of salbutamol, morning and evening asthma 
symptoms scores, and patient and investigator opinions 
of efficacy. The primary safety parameter was the 
morning serum cortisol level. Secondary safety variables 
included adverse events and adverse drug reactions, vital 
signs (heart rate and blood pressure), and investigator 
opinion of tolerability. 
Statistical analysis 
Sample size calculation (7) was based on the criteria of 
equivalent efficacy between the two treatments. 
Considering as the primary efficacy variable the final 
mean value of morning PEFR, the following was taken 
into account: the baseline-adjusted final mean value 
obtained in the BDP MDI group was estimated to equal 
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300 I min-1; the equivalence of efficacy between groups 
was defined as a difference between mean values not 
more than 10% of the BDP MDI mean; the standard 
deviation of the difference between mean values was 
estimated as equal to 70 I min-I; the expected difference 
between the mean value in the two groups was estimated 
as equal to 0; the power of the trial was defined as equal 
to 80% and the level of significance equal to 5%. 
With the exception of the main efficacy analysis, where 
statistical analysis was performed using a unilateral 
confidence interval, all P values and confidence intervals 
for percentages of change from baseline were calculated 
on a bilateral basis. Missing data were replaced with the 
LOCF (last observation carried forward) method. 
Statistical significance in the study was declared if 
P<O.OS. Baseline values were compared using a two-sided 
Mann-Whitney test for continuous variables, and by the 
Chi-square test or Fisher’s exact test for categorical 
variables.Values for parameters recorded on diary cards 
in the 24-hour run-in period, and values recorded at the 
end of the run-in period at the clinic, were considered as 
baseline. 
Within-treatment comparisons for morning PEFR 
were analysed by calculating the 95% confidence interval 
for the mean change from baseline, and between- 
treatment comparisons by using the analysis of 
covariance (ANCOVA) model at each l-week period. 
This model included terms for investigator and 
treatment effects and baseline value as a covariate. A 
preliminary test for the investigator-by-treatment 
interaction was undertaken at 0. IO significance leveLThe 
non-inferiority of BDP nebulization to BDP MDI was 
evaluated by calculating the lower limit of the unilateral 
95% confidence interval for the difference between the 
least square means (LSM), from ANCOVA, in the two 
groups, with BDP nebulization being defined as non- 
inferior to BDP MDI if this lower limit did not exceed 
10% of the LSM of the BDP MDI. 
Secondary efficacy parameters were analysed by 
calculating the 95% confidence interval for the mean 
change from baseline at each visit, and between- 
treatment comparisons were undertaken using 
ANCOVA. Patient and investigator opinions of efficacy 
were compared using the Chi-square test. 
Morning cortisol serum levels and cardiovascular 
parameters were analysed by calculating the 95% 
confidence intervals for the changes from baseline. 
Between-treatment comparisons for cortisol levels were 
made using the unpaired t test, for the incidence of 
adverse events, and adverse drug reactions, using the 
Chi-square test or the two-tailed Fisher’s exact test, and 
for investigator opinion of tolerability using the Chi- 
square test. 
RESULTS 
Patient population 
Of the 163 patients screened for the study, I5 I were 
randomized: 75 to the BDP nebulization group, and 76 to 
the BDP MDI group. Seven patients (all in the BDP 
nebulization group) were withdrawn during the active 
treatment period due to various reasons.The intent-to- 
treat (ITT) population was therefore made up of 144 
patients, the same as for the per protocol population 
since there were no major protocol deviations. 
Assessment of safety of the two treatments was based 
on the randomized population. For the additional 4-week 
study, 26 patients participated: I4 in the BDP 
nebulization group, and I2 in the BDP MDI group. Patient 
demography and values for lung function parameters at 
baseline were comparable for the two groups in the 
randomized population (Table I). 
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FIGURE I. Mean values for morning peak expiratory flow rate in (a) the randomized population of school-age children with asthma 
exacerbation at baseline and during 4 weeks of treatment with beclometasone dipropionate given by nebulization or metered-dose 
inhalation, and in (b) the completer population following an additional 4 weeks of treatment. 
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FIGURE 2. Mean values for various lung function parameters in (a) the intent-to-treat population of school-age children with asthma 
exacerbation before and after 4 weeIs of treatment with beclometasone dipropionate given by nebulization or metered-dose 
inhalation, and in (b) the completer population following an additional 4 weeks of treatment. 
Evaluation of efficacy: Morning PEFR 
Comparable and statistically significant improvements in 
morning PEFR were reported over baseline in both the 
BDP nebulization and BDP MDI groups at the end of the 
initial 4-week treatment period. In the BDP nebulization 
group, mean values increased from 233.2 I min-1 to 
322.0 I mini, while in the BDP MDI group the increase 
was from 222.9 I min-1 to 3 14.9 I mini (Figure I). The 
lower limit of the unilateral 95% confidence interval was 
-2 I .7 and did not exceed -IO% (-32.0 of the LSM of the 
BDP MDI group, thus demonstrating that BDP 
nebulization was not inferior to BDP MDI. In addition, 
the 95% bilateral confidence intervals for the difference 
between the LSM in the ANCOVA model was -20.6; 
25.4 and fell within 10% of the LSM of the BDP MDI 
group (k32.0 I min-I) to confirm that the two treatments 
were equivalent following 4 weeks of treatment. 
Moreover, in the additional 4-week treatment period 
mean morning PEFR values increased further for both 
groups in the completer population:from 342.6 I min-r at 
week 4 to 360.7 I min-1 at week 8 (P~0.0 12) in the BDP 
nebulization group, and from 296.5 I min-1 to 
3 17. I I min-’ (P=O. I9 I) in the BDP MDI group (Figure I). 
Evaluation of efficacy: Other measures 
of pulmonary function 
In the BDP nebulization group, evening PEFR improved 
statistically significantly from a mean of 24 I .7 I min-1 at 
baseline to 330.8 I min-I after 4 weeks’ treatment, and in 
the BDP MDI group from 237.1 I min-1 to 323.0 I min-I, 
with no significant difference noted between the two 
treatments (Figure 2). For the additional 4-week period 
of treatment, mean values increased progressively in the 
two groups from week 4 to week 8: from 354.9 I min-r 
to 37 I .O I mini in the BDP nebulization group, and from 
303.3 I min-1 to 3 18.4 I min-1 in the BDP MDI group 
(Figure 2). 
Mean FEV, rose statistically significantly in the BDP 
nebulization group from I .4 litres at day I to 2.0 litres at 
treatment end, and in the BDP MDI group from I .5 to 
2. I litres, with no significant between-group difference 
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noted (Figure 2). Mean values increased again for both 
groups in the additional 4-week period of treatment: 
from 2.2 litres at week 4 to 2.3 litres at week 8 in the 
BDP nebulization group, and from 2. I to 2.3 litres in the 
BDP MDI group (Figure 2). 
In the BDP nebulization group, mean FVC increased 
statistically significantly from I.8 litres at day I to 
2.3 litres after 4 weeks’ treatment, and in the BDP MDI 
group from I .8 to 2.4 litres, with no significant difference 
found between the two treatments (Figure 2). In the 
additional 4-week treatment period, further increases in 
mean values were reported: from 2.6 litres at week 4 to 
2.7 litres at week 8 and from 2.6 to 2.8 litres in the BDP 
nebulization and BDP MDI groups, respectively (Figure 2). 
Evaluation of efficacy: Signs and 
symptoms and rescue medication 
Following treatment for 4 weeks, superimposable and 
statistically significant improvements in morning and 
evening asthma symptoms scores were reported for the 
two treatment arms. Mean values fell in both groups from 
I.8 at baseline to 0.4 at treatment end for morning 
scores, and from I *9 to O-4 in the BDP nebulization group 
and I .9 to 0.5 in the BDP MDI group in evening scores. 
Moreover, in the additional 4-week treatment period 
improvements were maintained or further enhanced in 
both groups, with mean morning scores falling from 0.6 at 
week 4 to 0.4 at week 8 in the BDP nebulization group, 
and from I.0 to 0.7 in the BDP MDI group, and mean 
evening scores from 0.6 to 0.4 in the BDP nebulization 
group, and from I.0 to 0.9 in the BDP MDI group. 
Equivalent statistically significant reductions were also 
reported in morning and evening salbutamol consump- 
tion in both groups at the end of the 4-week treatment 
period when compared with baseline. For morning 
consumption, the mean number of puffs fell from 
O-8 puffs day-r to 0.3 puffs day-l in the BDP nebulization 
group, and from 0.9 puffs day- to 0.2 puffs dayi in the 
BDP MDI group, and for evening consumption from 
2.1 puffs day’ to 0.5 puffs day’ in the BDP nebulization 
group, and from I .9 puffs dayi to 0.6 puffs day-r in the 
BDP MDI group. Values remained stable or further 
declined for the additional 4-week treatment period: 
changes from O-5 puffs day’ at week 4 to 0.3 puffs day’ 
at week 8 were noted for the BDP nebulization group, 
and from O-3 puffs day’ to 0.2 puffs day’ in the BDP 
MDI group, for morning use; and from I. I puffs day-r to 
0.7 puffs day-r in the BDP nebulization group, and from 
I .O puffs day-r to I .I puffs day-r in the BDP MDI group, 
for evening use. 
Evaluation of efficacy: Patient and 
investigator opinions 
According to patient opinion, almost all patients in both 
treatment groups considered efficacy as ‘excellent’ or 
‘good’ (98.5% and 100% of patients in the BDP nebuliza- 
tion and BDP MDI groups, respectively), with no 
significant difference noted between the two treatment 
arms. Similarly, according to investigator opinion nearly all 
patients in the two groups reported efficacy as ‘excellent’ 
or ‘good’ (9 I .3% and 97.4% in the BDP nebulization and 
BDP MDI groups, respectively), with the between- 
treatment difference again being non-significant. 
Evaluation of safety 
Safety data showed that both treatments were well 
tolerated. During the treatment period, 25 (33.3%) patients 
in the BDP nebulization group and 26 (34.2%) in the BDP 
MDI group reported adverse events (NS between 
treatments) (Table 2). The respective number of adverse 
events was 43 and 48, and these were generally mild. 
The two treatments had a comparable effect with 
respect to morning serum cortisol levels, and no 
clinically relevant changes were reported for vital signs in 
either group (NS between treatments). Furthermore, 
investigator opinion of tolerability was ‘excellent’ or 
‘good’ for all patients in both groups, with no significant 
difference noted between the two treatments. 
DISCUSSION 
This study was designed to evaluate the efficacy and 
safety of a new formulation of BDP suspension for 
nebulization given via a nebulizer and BDP spray given 
using an MDI plus spacer as a 4-week treatment for 
moderate-severe asthma exacerbation in paediatric 
patients. An additional 4-week treatment period was 
undertaken in order to verify if patients could benefit 
from longer maintenance therapy at half doses. 
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Although no previous studies have compared the 
effects of BDP delivered by nebulizer and MDI, two 
studies in asthmatic children assessed the effects of 
terbutaline via either nebulizer or MDI plus spacer. One 
study of I2 asthmatic children found no statistical 
difference in FEV, increase between 500 pg terbutaline 
via MDI and 4 mg by nebulizer, although the direction of 
effect did favour the latterAt I mg MDI there was again 
no statistical difference but the direction of effect 
favoured the MDI (8). A second study involving 22 
asthmatic children found no statistical difference in any 
measures of lung function or patient-reported symptom 
scores following administration of terbutaline by MDI or 
nebulizer with an MDI:nebulizer dose ratio of I:4 (9). 
The results of this study demonstrated that nebulized 
and MDI forms of BDP significantly, and to a similar 
degree, improved pulmonary function and asthma 
symptoms scores, and reduced the need for rescue 
medication. Almost all patients in both groups also 
considered efficacy to be ‘good’ or ‘excellent’. Moreover, 
statistical analysis of the results for the primary efficacy 
variable of morning PEFR confirmed that BDP 
nebulization was not inferior to BDP MDI and that the 
two treatments were equivalent. Furthermore, improve- 
ments were maintained or further enhanced when both 
treatments were used for an additional 4 weeks at half 
doses. The improvements in pulmonary function tests 
and symptoms, and the equivalence between the two 
delivery systems, are noteworthy if it is taken into 
account that the children were suffering from asthma 
exacerbation and had FEV, values of around 60% of the 
predicted normal (moderately to severe exacerbation) at 
study entry. Consequently, there was wide scope for 
improvement, and the results show that normal 
pulmonary function was restored following treatment 
and by a similar extent with the two delivery systems. In 
addition, the safety profile was comparable for the two 
groups with respect to the incidence of adverse events, 
potential adrenal suppression (as indicated by morning 
serum cortisol levels), and vital signs. 
In conclusion, this study demonstrates that BDP 
suspension for nebulization 1600 ug day-1 given via a 
nebulizer and BDP spray 800 ,ug day-’ given via an MDI 
plus spacer are effective and therapeutically equivalent, 
with a good safety and tolerability profile, when used as 
a treatment for asthma exacerbation in school-age 
children. 
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